ArticleContemporary clinical trials2025
Strengthening Older Adults Remembering (SOARing): Research protocol for a multi-site randomized clinical trial examining the efficacy of the Kessler Foundation modified Story Memory Technique (KF-mSMT®) in Mild Cognitive Impairment (MCI).
Article in Contemporary clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundLong-term memory dysfunction is the hallmark feature of amnestic mild cognitive impairment (aMCI) resulting in substantial negative impact on everyday functioning and quality of life. The Kessler Foundation modified Story Memory Technique (KF-mSMT®) is a 10-session memory rehabilitation protocol in which participants are taught to utilize imagery and context to facilitate learning. This paper describes the protocol for a double blind, placebo controlled, randomized clinical trial (RCT) examining the efficacy of the KF-mSMT® in persons who meet criteria for aMCI.
methodsParticipants will undergo baseline assessments consisting of neuropsychological testing, neuroimaging, self-report questionnaires, and a blood draw for measuring plasma biomarkers. Participants will then be randomized to one of two conditions using concealed allocation: KF-mSMT® or an active placebo control condition consisting of memory exercises. Participants will be blinded to condition. Within 2 weeks of completing the intervention, participants will complete the same measures as at baseline administered by treatment-blinded assessors. The primary study outcome is new learning and memory measured by neuropsychological assessment (Open Trial Selective Reminding Test). Secondary outcomes include other measures of learning and memory (i.e. Repeatable Battery for the Assessment of Neuropsychological Status story), visuospatial memory (Brief Visuospatial Memory Test-Revised)) as well as everyday memory (Ecological Memory Simulations, Object Location Touchscreen Test), neuroimaging and plasma biomarkers.
conclusionIf successful, this trial will provide Class I evidence supporting the application of the KF-mSMT® for treating MCI-related learning and memory decline in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.